Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Seelos Therapeutics Inc (SEEL)

Seelos Therapeutics Inc (SEEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,647
  • Shares Outstanding, K 13,681
  • Annual Sales, $ 2,200 K
  • Annual Income, $ -37,880 K
  • 60-Month Beta 1.97
  • Price/Sales 6.52
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade SEEL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -12.01
  • Most Recent Earnings $-8.41 on 11/14/23
  • Latest Earnings Date 03/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 107.16%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7550 +21.56%
on 02/21/24
1.3600 -32.51%
on 03/01/24
+0.0888 (+10.71%)
since 02/16/24
3-Month
0.7071 +29.80%
on 02/07/24
1.9300 -52.45%
on 01/09/24
-0.6822 (-42.64%)
since 12/18/23
52-Week
0.7071 +29.80%
on 02/07/24
49.8000 -98.16%
on 08/03/23
-18.9602 (-95.38%)
since 03/17/23

Most Recent Stories

More News
This May be One of the Biggest Catalysts for Psychedelic Stocks in 2024

About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression....

CMPS : 9.79 (-1.11%)
SEEL : 0.9178 (-7.99%)
ATAI : 1.6700 (-5.65%)
MNMD : 9.91 (+8.07%)
NUMI.TO : 0.1000 (unch)
NUMIF : 0.0771 (-0.64%)
Breaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSD

At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change...

CMPS : 9.79 (-1.11%)
SEEL : 0.9178 (-7.99%)
ATAI : 1.6700 (-5.65%)
MNMD : 9.91 (+8.07%)
NUMI.TO : 0.1000 (unch)
NUMIF : 0.0771 (-0.64%)
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 0.6200 (+1.64%)
MMED.NE : 13.4500 (+10.70%)
CYBN : 0.4500 (-2.17%)
ATAI : 1.6700 (-5.65%)
MNMD : 9.91 (+8.07%)
SEEL : 0.9178 (-7.99%)
CMPS : 9.79 (-1.11%)
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...

SEEL : 0.9178 (-7.99%)
Stock Index Futures Plunge on Fed’s Hawkish Stance, BoE Decision in Focus

December S&P 500 futures (ESZ23) are down -0.42%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.65% this morning as Treasury yields jumped after the Federal Reserve signaled interest rates...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
NVDA : 884.55 (+0.70%)
MSFT : 417.32 (+0.22%)
CHWY : 16.84 (-3.16%)
WDC : 59.31 (-0.80%)
COTY : 12.09 (-2.03%)
JD-.LN : 109.850 (-1.17%)
FDX : 253.18 (-0.04%)
ULCC : 7.28 (-2.28%)
HQY : 82.96 (+1.87%)
TRNS : 109.23 (-2.69%)
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update

- Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior...

SEEL : 0.9178 (-7.99%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 0.6200 (+1.64%)
MMED.NE : 13.4500 (+10.70%)
CYBN : 0.4500 (-2.17%)
CMPS : 9.79 (-1.11%)
SEEL : 0.9178 (-7.99%)
MNMD : 9.91 (+8.07%)
NUMIF : 0.0771 (-0.64%)
NUMI.TO : 0.1000 (unch)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...

NUMI.TO : 0.1000 (unch)
CYBN : 0.4500 (-2.17%)
CMPS : 9.79 (-1.11%)
MNMD : 9.91 (+8.07%)
SEEL : 0.9178 (-7.99%)
NUMIF : 0.0771 (-0.64%)
Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...

SEEL : 0.9178 (-7.99%)
Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...

SEEL : 0.9178 (-7.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which...

See More

Key Turning Points

3rd Resistance Point 1.0819
2nd Resistance Point 1.0459
1st Resistance Point 0.9819
Last Price 0.9178
1st Support Level 0.8819
2nd Support Level 0.8459
3rd Support Level 0.7819

See More

52-Week High 49.8000
Fibonacci 61.8% 31.0465
Fibonacci 50% 25.2535
Fibonacci 38.2% 19.4606
Last Price 0.9178
52-Week Low 0.7071

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar